A new National Academies report recommends ways for the U.S. to reap the benefits of artificial intelligence in biotechnology ...

The field of cancer treatment has long struggled with the immense costs and time-consuming nature of drug development.

Alongside new steps in its therapeutic pipeline—and a new push into laboratory robotics—Insilico Medicine has raised $110 ...

BullFrog AI plans to introduce what it considers a game-changing approach that could shorten timelines, reduce costs, and increase success rates in drug development.

Insilico Medicine, whose Hong Kong IPO application lapsed in 2024, is still considering going public in the city, said ...

In essence, the future of AI is inextricably linked to advancements in data management, making it an indispensable enabler of ...

Pheiron and Ribo are excited to announce that the first two strategic collaboration milestones have been successfully ...

The New Normal Five years ago, COVID-19 was declared a global pandemic, marking the official onset of a healthcare crisis ...

Insilico Medicine Inc. is considering an initial public offering after securing funding at a valuation of more than $1 ...

The collaboration will leverage Nosis’ Connexa™ platform, an advanced AI-powered drug design and delivery system, to enable therapeutic access to extrahepatic cell types across multiple vital ...

Novo Nordisk and AI-driven protein design company Gensaic are to develop tissue-targeted therapies for cardiometabolic ...